AMAG Pharmaceuticals, Inc. Expected to Post FY2019 Earnings of $0.68 Per Share (AMAG)
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) – Stock analysts at Leerink Swann issued their FY2019 EPS estimates for AMAG Pharmaceuticals in a report released on Tuesday. Leerink Swann analyst J. Schwartz anticipates that the specialty pharmaceutical company will earn $0.68 per share for the year. Leerink Swann currently has a “Market Perform” rating and a $25.00 target price on the stock.
AMAG Pharmaceuticals (NASDAQ:AMAG) last announced its quarterly earnings data on Tuesday, February 14th. The specialty pharmaceutical company reported ($0.31) EPS for the quarter, missing the Zacks’ consensus estimate of $0.24 by $0.55. AMAG Pharmaceuticals had a return on equity of 11.10% and a net margin of 3.12%. The company had revenue of $151.60 million for the quarter, compared to analyst estimates of $155.12 million. During the same period in the prior year, the firm posted $1.12 earnings per share. The business’s quarterly revenue was up 39.5% compared to the same quarter last year. COPYRIGHT VIOLATION NOTICE: “AMAG Pharmaceuticals, Inc. Expected to Post FY2019 Earnings of $0.68 Per Share (AMAG)” was posted by Financial Market News and is owned by of Financial Market News. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at http://www.financial-market-news.com/amag-pharmaceuticals-inc-expected-to-post-fy2019-earnings-of-0-68-per-share-amag/1406135/.
AMAG has been the topic of several other research reports. Cantor Fitzgerald raised their price target on AMAG Pharmaceuticals from $24.00 to $25.00 and gave the stock a “neutral” rating in a report on Monday, March 6th. Jefferies Group LLC reissued a “buy” rating and issued a $40.00 price target (down previously from $45.00) on shares of AMAG Pharmaceuticals in a report on Wednesday, February 15th. Needham & Company LLC downgraded AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, January 11th. Janney Montgomery Scott began coverage on AMAG Pharmaceuticals in a report on Tuesday, January 3rd. They issued a “buy” rating and a $45.00 price target on the stock. Finally, Guggenheim cut their price target on AMAG Pharmaceuticals from $42.00 to $28.00 and set a “buy” rating on the stock in a report on Thursday, February 2nd. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and two have assigned a buy rating to the stock. AMAG Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $32.00.
Shares of AMAG Pharmaceuticals (NASDAQ:AMAG) traded up 0.333% during trading on Friday, hitting $22.625. The stock had a trading volume of 416,878 shares. The company’s market cap is $776.92 million. AMAG Pharmaceuticals has a one year low of $17.92 and a one year high of $36.83. The stock’s 50-day moving average price is $22.82 and its 200-day moving average price is $26.53.
A number of hedge funds have recently made changes to their positions in the stock. Acadian Asset Management LLC increased its position in shares of AMAG Pharmaceuticals by 20.8% in the third quarter. Acadian Asset Management LLC now owns 4,520 shares of the specialty pharmaceutical company’s stock valued at $111,000 after buying an additional 777 shares in the last quarter. Nisa Investment Advisors LLC increased its position in shares of AMAG Pharmaceuticals by 1,666.7% in the third quarter. Nisa Investment Advisors LLC now owns 5,300 shares of the specialty pharmaceutical company’s stock valued at $130,000 after buying an additional 5,000 shares in the last quarter. Sei Investments Co. increased its position in shares of AMAG Pharmaceuticals by 93.3% in the third quarter. Sei Investments Co. now owns 8,287 shares of the specialty pharmaceutical company’s stock valued at $204,000 after buying an additional 4,000 shares in the last quarter. Seven Eight Capital LP purchased a new position in shares of AMAG Pharmaceuticals during the fourth quarter valued at $212,000. Finally, Gargoyle Investment Advisor L.L.C. purchased a new position in shares of AMAG Pharmaceuticals during the third quarter valued at $220,000.
About AMAG Pharmaceuticals
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.